Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20100735 | 0.86 | SMN1; SMN2 (0.34) | ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL20113587 | 0.83 | ALDH1A1 (0.37) | ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL20104861 | 0.83 | PTGS2 (0.36) | ALDH1A1LMNAMAPTSMN1; SMN2PTGS2 | |
| SCHEMBL20109406 | 0.82 | SMN1; SMN2 (0.36) | ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL20104867 | 0.82 | HPGD (0.39) | ALDH1A1SMN1; SMN2PTGS2PTGS1 | |
| SCHEMBL20113580 | 0.81 | FAAH (0.39) | PTGS2PTGS1 | |
| SCHEMBL13396860 | 0.81 | ALDH1A1 (0.38) | ALDH1A1PTGS2PTGS1 | |
| SCHEMBL20104906 | 0.81 | HPGD (0.42) | ALDH1A1LMNAMAPTSMN1; SMN2PTGS2 | |
| SCHEMBL16124693 | 0.80 | PTGS2 (0.33) | PTGS2PTGS1 | |
| SCHEMBL13863668 | 0.79 | TSHR (0.41) | ALDH1A1LMNAMAPTPTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10280138-B2 | Nitric oxide donating derivatives of fluprostenol | NICOX S.A. (FR) | 2019-05-07 | — | — | US | disclosed |
| US-20180118676-A1 | NITRIC OXIDE DONATING DERIVATIVES OF LATANOPROST FREE ACID | NICOX S.A. (FR) | 2018-05-03 | — | — | US | disclosed |
| US-20180118677-A1 | NITRIC OXIDE DONATING DERIVATIVES OF FLUPROSTENOL | NICOX S.A. (FR) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118677-A1 | NITRIC OXIDE DONATING DERIVATIVES OF FLUPROSTENOL | PTGIS, NOS2, PTGIR | ALDH1A1 584/4885LMNA 3760/4885MAPT 4113/4885 |
| US-10280138-B2 | Nitric oxide donating derivatives of fluprostenol | PTGIS, NOS2, PTGIR | ALDH1A1 584/4885LMNA 3760/4885MAPT 4113/4885 |
| US-20180118676-A1 | NITRIC OXIDE DONATING DERIVATIVES OF LATANOPROST FREE ACID | PTGIS, NOS2, NOS1 | ALDH1A1 665/4885LMNA 2439/4885MAPT 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.